Related Experiment Video
Updated: Jun 5, 2026
09:42
Generating Transgenics and Knockouts in Strongyloides Species by Microinjection
Published on: October 7, 2021
Transgenic hookworm secretes anti-tetrodotoxin human single chain antibody
Kumar Sachin Singh1, Suman Bharti1, Bruce A Rosa1
1Division of Infectious Diseases, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Nature Communications
|June 3, 2026
Summary
Bioengineered hookworms can produce and deliver biologic drugs within the host. This novel platform offers a potential long-term, single-dose therapy for chronic diseases, improving patient compliance and reducing costs.
Area of Science:
- Biotechnology
- Parasitology
- Drug Delivery Systems
Background:
- Biologics offer effective treatments but require parenteral administration and frequent dosing, limiting patient compliance and increasing costs.
- There is a critical need for innovative platforms for sustained, safe, and efficient in vivo delivery of biologic therapeutics.
- Current delivery methods for biologics face challenges in long-term efficacy and patient adherence.
Purpose of the Study:
- To develop a novel bioengineered hookworm platform for in vivo manufacturing and delivery of biologic therapeutics.
- To demonstrate the feasibility of genetically engineering hookworms to produce and secrete therapeutic proteins.
- To assess the potential of this platform for long-term, single-administration treatment of chronic diseases.
Main Methods:
- Genetic engineering of Ancylostoma ceylanicum hookworms to express a human single-chain variable fragment antibody (s16-HuScFv).
- Insertion of the s16-HuScFv transgene into the hookworm genome, confirming heritable transgenesis and assessing gene expression.
- Evaluation of the secreted s16-HuScFv product in host circulation for its therapeutic activity (neutralization of tetrodotoxin).
Main Results:
- Successful engineering of Ancylostoma ceylanicum to express the s16-HuScFv transgene without disrupting endogenous gene expression.
- Confirmation of heritable transgenesis and secretion of the s16-HuScFv protein into the host's bloodstream.
- Demonstrated partial neutralization of tetrodotoxin by the secreted s16-HuScFv, validating the therapeutic potential.
Conclusions:
- The bioengineered hookworm platform provides a viable strategy for in vivo production and sustained delivery of biologic therapeutics.
- This disease-agnostic platform, utilizing a single-dose administration, holds promise for managing chronic human diseases with improved patient compliance.
- Further development of this innovative approach could revolutionize long-term biologic therapy delivery within the host.
